Develops small molecule medicines for brain disorders.
Jun 2026Revenue $1.58M/yrExpenses $59.9M/yr
No trendCash runway ≈ 2.1 years from Jun 2026
Figures by year
When will Ovid Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.58M and expenses $59.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $7.25M | $49.7M | −$42.4M |
| Dec 2024 | $566K | $62.5M | −$61.9M |
| Dec 2023 | $392K | $59.7M | −$59.3M |
| Dec 2022 | $1.50M | $57.1M | −$55.5M |
| Dec 2021 | $208M | $84.2M | $124M |
| Dec 2020 | $12.6M | $94.0M | −$81.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.